This article first appeared on GuruFocus .
Release Date: May 14, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Crescent Capital BDC Inc ( NASDAQ:CCAP ) has reduced its base management fee from 1.25% to 1% and the incentive fee from 17.5% to 15%, effective April 1, 2026, making its fee structure more competitive.
-
The company has implemented structural changes to position itself for consistent earnings and attractive returns across market cycles.
-
CCAP generated $0.38 per share of net investment income for the quarter, with a reported NII of $0.42 per share after a $0.04 per share incentive fee waiver.
-
The portfolio is well-positioned with a focus on first lien investments, non-cyclical industries, and strong sponsor backing, informed by Crescent's 35-year track record.
-
CCAP benefits from being part of the broader Crescent platform, which is seeing an increasingly attractive opportunity set with widening spreads and reduced competition for new investments.
Negative Points
-
Net investment income per share decreased from $0.45 in the prior quarter to $0.38, primarily due to an increase in non-accruals and a reduction in base rates.
-
Net asset value declined from $19.10 per share to $18.27 per share, driven by broader market conditions and credit-specific depreciation.
-
Non-accruals increased to 5.7% of cost and 3.6% of fair value, reflecting the addition of five new non-accruals during the quarter.
-
The company reset its quarterly base dividend from $0.42 to $0.34 per share, reflecting a conservative level relative to its near-term earnings outlook.
-
CCAP's leverage ended the quarter at 1.32 times, slightly above the target range of 1.1 to 1.3 times, due to the timing of realizations being pushed out of the quarter.
Q & A Highlights
Q: How comfortable are you with the current issues in the healthcare sector within your portfolio, and are there still developments that could catch you by surprise? A: Henry Chung, President: We have observed stress in select healthcare names, but it's not broad-based. The issues are distinct across different investments, such as labor costs or execution-related challenges. We have been monitoring these closely and feel we have a good handle on where to focus, although we recognize potential volatility in performance quarter-to-quarter.
Q: How much have inflation and wage inflation exacerbated the issues in your portfolio, and is there a risk of further deterioration? A: Henry Chung, President: Wage inflation has been a persistent issue, and while the rate of increase has slowed, it remains elevated. We don't expect a reversal of these trends and have factored this into our asset valuations and accrual status. We aim to be conservative in our approach.
Q: Are all your non-accruals sponsored companies, and are sponsors receiving any dividends from these investments? A: Henry Chung, President: Yes, all non-accruals are sponsor-backed companies. Typically, any dividends or management fees to sponsors are halted well before we determine accrual status, as these cash outflows are subordinated to our debt service.
Q: Given the stress in private equity, does this create a greater risk to your business model since sponsors may have less capacity to support problematic businesses? A: Jason Breaux, CEO: Elevated credit stress in BDCs indicates challenges for sponsors as well. We aim to select credits that sponsors will continue to support. While there will be triage across sponsor-backed portfolios, our focus is on picking credits with minimal risk of impairment.
Q: Will the Sun Life acquisition enable you to get lower-cost debt funding going forward? A: Jason Breaux, CEO: Sun Life has been a supportive capital partner, owning equity and unsecured debt in CCAP. They are a dominant player in the private placement market, which supports us across various strategies.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
